ATE273707T1 - Antibiotische pharmazeutische formulierung mit lysergol zur verstärkung der wirksamkeit und behandlungsmethode - Google Patents

Antibiotische pharmazeutische formulierung mit lysergol zur verstärkung der wirksamkeit und behandlungsmethode

Info

Publication number
ATE273707T1
ATE273707T1 AT02716990T AT02716990T ATE273707T1 AT E273707 T1 ATE273707 T1 AT E273707T1 AT 02716990 T AT02716990 T AT 02716990T AT 02716990 T AT02716990 T AT 02716990T AT E273707 T1 ATE273707 T1 AT E273707T1
Authority
AT
Austria
Prior art keywords
lysergol
treatment method
pharmaceutical formulation
enhance effectiveness
antibiotic pharmaceutical
Prior art date
Application number
AT02716990T
Other languages
English (en)
Inventor
Suman Khanuja
Jai Shankar Arya
Santosh Srivastava
Ajit Kumar Shasany
Tiruppadiripuliyur Kumar
Mahendra Pandurang Darokar
Sushil Kumar
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Priority claimed from PCT/IB2002/001125 external-priority patent/WO2003080059A1/en
Application granted granted Critical
Publication of ATE273707T1 publication Critical patent/ATE273707T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02716990T 2002-03-25 2002-03-25 Antibiotische pharmazeutische formulierung mit lysergol zur verstärkung der wirksamkeit und behandlungsmethode ATE273707T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/001125 WO2003080059A1 (en) 2002-03-25 2002-03-25 Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment

Publications (1)

Publication Number Publication Date
ATE273707T1 true ATE273707T1 (de) 2004-09-15

Family

ID=28053160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02716990T ATE273707T1 (de) 2002-03-25 2002-03-25 Antibiotische pharmazeutische formulierung mit lysergol zur verstärkung der wirksamkeit und behandlungsmethode

Country Status (6)

Country Link
EP (1) EP1370263B1 (de)
AT (1) ATE273707T1 (de)
AU (1) AU2002247911A1 (de)
CA (1) CA2441629C (de)
DE (1) DE60201022T2 (de)
ES (1) ES2225777T3 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102134239B (zh) * 2009-12-15 2012-10-24 戈埃尔·帕万·库马 从裂叶牵牛中提取高纯度麦角醇的方法

Also Published As

Publication number Publication date
EP1370263B1 (de) 2004-08-18
ES2225777T3 (es) 2005-03-16
CA2441629C (en) 2010-09-21
EP1370263A1 (de) 2003-12-17
AU2002247911A1 (en) 2003-10-08
CA2441629A1 (en) 2003-10-02
DE60201022T2 (de) 2005-08-18
DE60201022D1 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
CL2003002353A1 (es) Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
CL2003002287A1 (es) COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
UY27720A1 (es) Aroilpiridinonas monocíclicas,
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
MY143795A (en) Tetrahydropyridoindole derivatives
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
TW200501947A (en) Stabilized pharmaceutical composition comprising an amorphous active substance
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE502005006427D1 (de) Substituierte azachinazoline mit antiviraler wirkung
CL2004002030A1 (es) Uso de interferon y ribavirina porque sirve para preparar un medicamento para tratar infecciones virales; composicion farmaceutica que comprende interferon, ribavirina y opcionalmente antioxidante; kit y su uso para preparar un medicamento para trata
ATE446763T1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
ATE273707T1 (de) Antibiotische pharmazeutische formulierung mit lysergol zur verstärkung der wirksamkeit und behandlungsmethode
BRPI0407850A (pt) processo para fabricação de uma composição farmacêutica contendo o princìpio ativo fenofibrato ou de um de seus derivados, e, comprimido de fenofibrato ou de um de seus derivados
WO2003080568A3 (en) Probucol derivatives
BR0316021A (pt) Comibinação compreendendo um inibidor de cdk e cisplatina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties